Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

<h4>Background</h4> <p>The multiple disease domains affected in psoriatic arthritis (PsA) may make composite endpoints appropriate for assessing changes in disease activity over time. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Data from two phase 3 stu...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Helliwell, P, Coates, L, Fitzgerald, O, Nash, P, Soriano, E, Husni, M, Hsu, M, Kanik, K, Hendrikx, T, Wu, J, Kudlacz, E
Fformat:	Journal article
Cyhoeddwyd:	BioMed Central 2018

Eitemau Tebyg

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
gan: Philip Helliwell, et al.
Cyhoeddwyd: (2018-10-01)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
gan: Helliwell, P, et al.
Cyhoeddwyd: (2018)

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
gan: Nash, P, et al.
Cyhoeddwyd: (2018)

Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study
gan: Nash, P, et al.
Cyhoeddwyd: (2018)

Janus kinase inhibitors in the treatment of psoriatic arthritis
gan: E. Yu. Loginova, et al.
Cyhoeddwyd: (2022-02-01)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
gan: Coates, L, et al.
Cyhoeddwyd: (2016)

Assessing disease activity in psoriatic arthritis: a literature review
gan: Tucker, L, et al.
Cyhoeddwyd: (2018)

A novel treatment for psoriatic arthritis: Janus kinase inhibitors
gan: Miao Chen, et al.
Cyhoeddwyd: (2020-04-01)

Sustained very low disease activity and remission in psoriatic arthritis patients
gan: Lubrano, E, et al.
Cyhoeddwyd: (2019)

Current concepts and unmet needs in psoriatic arthritis
gan: Mahmood, F, et al.
Cyhoeddwyd: (2017)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
gan: Nash, P, et al.
Cyhoeddwyd: (2018)

Remission in psoriatic arthritis—where are we now?
gan: Coates, L, et al.
Cyhoeddwyd: (2017)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
gan: P.S. Helliwell
Cyhoeddwyd: (2011-09-01)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
gan: Ennio Lubrano, et al.
Cyhoeddwyd: (2019-08-01)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
gan: Coates, LC, et al.
Cyhoeddwyd: (2024)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
gan: Coates, L, et al.
Cyhoeddwyd: (2021)

Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
gan: Coates, L, et al.
Cyhoeddwyd: (2018)

Best-practice indicators in Psoriatic disease care
gan: Helliwell, P, et al.
Cyhoeddwyd: (2019)

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation
gan: Coates, L, et al.
Cyhoeddwyd: (2016)

What should be the primary target of "treat to target" in psoriatic arthritis?
gan: Coates, LC, et al.
Cyhoeddwyd: (2018)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
gan: Peter Nash, et al.
Cyhoeddwyd: (2018-11-01)

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
gan: Mease, P, et al.
Cyhoeddwyd: (2018)

Psoriatic arthritis
gan: FitzGerald, O, et al.
Cyhoeddwyd: (2021)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
gan: Laura C. Coates, et al.
Cyhoeddwyd: (2021-03-01)

Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
gan: Jiao Wang, et al.
Cyhoeddwyd: (2025-02-01)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
gan: Coates, L, et al.
Cyhoeddwyd: (2022)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
gan: Soriano, ER, et al.
Cyhoeddwyd: (2023)

Psoriatic Arthritis: A Review
gan: Farrouq Mahmood, et al.
Cyhoeddwyd: (2016-07-01)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
gan: Helliwell, PS, et al.
Cyhoeddwyd: (2021)

Nail disease in psoriatic arthritis. Data from the Russian Psoriatic Arthritis Registry
gan: E. E. Gubar, et al.
Cyhoeddwyd: (2021-10-01)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
gan: Laure Gossec, et al.
Cyhoeddwyd: (2024-02-01)

How should we define disease and outcomes in axial psoriatic arthritis?
gan: Coates, LC
Cyhoeddwyd: (2021)

Hot topice debate: preventing psoriatic arthritis in patients with psoriasis
gan: Vivekanantham, A, et al.
Cyhoeddwyd: (2024)

Measuring outcomes in psoriatic arthritis
gan: Ogdie, A, et al.
Cyhoeddwyd: (2020)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
gan: Vishal R. Tandon, et al.
Cyhoeddwyd: (2022-07-01)

Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
gan: Braun, J, et al.
Cyhoeddwyd: (2023)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
gan: Philip J. Mease, et al.
Cyhoeddwyd: (2023-08-01)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
gan: Yazji, SM, et al.
Cyhoeddwyd: (2025)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
gan: Nash, P, et al.
Cyhoeddwyd: (2021)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
gan: Coates, LC, et al.
Cyhoeddwyd: (2022)